Prostate Cancer Treatment Devices Market - By Device Type (Radiation Treatment Device, Surgical Treatment Devices, Ablation Treatment Devices), By End-use (Hospitals, Specialty Clinics, Ambulatory Surgical Centers), & Forecast, 2023 – 2032

Prostate Cancer Treatment Devices Market Size

Prostate Cancer Treatment Devices Market size valued at around USD 3.4 billion in 2022 and is estimated to grow at over 11.5% CAGR between 2023 and 2032. This market revenue is attributable to the various factors comprising increasing prevalence of prostate cancer, technological advancements, growing adoption of robotic-assisted surgeries, etc. The Rising prevalence of prostate cancer is set to drive the demand for treatment devices. Robotic-assisted surgeries, such as robot-assisted radical prostatectomy (RARP), have gained popularity in the treatment of prostate cancer. These surgical robots offer enhanced precision, reduced invasiveness, shorter recovery times, and improved patient outcomes.
 

Additionally, minimally invasive procedures for prostate cancer treatment such as laparoscopic and robotic surgeries have witnessed increased adoption due to their advantages including reduced post-operative complications, shorter hospital stays, and faster recovery. As a result, the market for prostate cancer treatment devices is expected to expand globally, driven by the increasing prevalence of prostate cancer, growing adoption of robotic-assisted surgeries, and rising demand for minimally invasive procedures in emerging economies.
 

Prostate cancer treatment devices refer to medical devices or tools specifically designed and used in the diagnosis, treatment, or management of prostate cancer. These devices are utilized by healthcare professionals, including urologists and oncologists, to aid in the detection, staging, and treatment of prostate cancer.
 

The stringent regulatory framework related to prostate cancer treatment devices may hamper the market growth. The U.S. FDA has rigid regulatory compliances and complex approval procedures that may obstruct the prostate cancer treatment devices market growth. The majority of such devices need a premarket notification, or 510(k) process prior to their commercialization in the market. Such stringent product regulations may lead to penalties and loss of market access in a global marketplace.
 

Further, regulations majorly delay the approval of these products due to time-consuming documentation and review protocols. These products usually require the optimum level of scrutiny and a set of entire preclinical & clinical reviews through pre-market approvals, with the majority requiring clinical studies and subsequent information. These additional controls include mandates such as post-market surveillance, special labelling requirements, and meeting the pre-set performance standards. Thus, such stringent regulatory frameworks related to prostate cancer treatment devices may limit industry growth over the coming years.
 

COVID-19 Impact

The COVID-19 pandemic has had a negative impact on the prostate cancer treatment devices markets. During the pandemic, healthcare systems worldwide faced immense pressure due to the surged number of COVID-19 cases. As a result, many routine and non-urgent medical procedures including cancer screenings and treatments were delayed or postponed. This delay in diagnosis and treatment had an impact on the demand for prostate cancer treatment devices. Non-essential surgeries and treatments were delayed prioritizing COVID-19 patients. This had led to decreased utilization of prostate cancer treatment devices during the pandemic. The global medical device supply chain experienced disruptions during the pandemic and these disruptions had led to delays in the production, distribution, and availability of prostate cancer treatment devices, impacting market growth.
 

Prostate Cancer Treatment Devices Market Trends

Prostate cancer treatment devices have witnessed significant technological advancements in recent years. These advancements are intended to improve the accuracy and effectiveness of cancer diagnostics, staging, and treatment options.  Robotic-assisted surgery comprising the da Vinci Surgical System has revolutionized prostate cancer treatment though enabling minimally invasive procedures with smaller incisions, reduced blood loss, and faster recovery times. Advancements in technology such as real-time ultrasound imaging and thermal mapping have improved the accuracy and safety of cryotherapy procedures. This approach is particularly useful for localized prostate cancer and can be performed on an outpatient basis. Advances in genomic profiling and molecular diagnostics have led to the development of targeted therapies for advanced prostate cancer. These therapies aim to inhibit specific genetic mutations or pathways involved in cancer growth.
 

Moreover, brachytherapy involves the implantation of tiny radioactive seeds directly into the prostate gland. Technological advancements have allowed for better seed placement using real-time imaging guidance such as ultrasound or CT scans. This approach delivers high doses of radiation to the prostate while minimizing exposure to surrounding tissues. Overall, technological advancements hold promise in improving prostate cancer treatment efficiently.
 

Prostate Cancer Treatment Devices Market Analysis

Based on device type, the prostate cancer treatment devices market is segmented as radiation treatment devices, surgical treatment devices, ablation treatment devices, and others. The radiation treatment devices segment held the dominant market share in 2022 and was valued at over USD 1.4 billion. This dominant market share is owing to the several advantages associated with the radiation devices in the treatment of prostate cancer. Radiation therapy can offer curative potential for localized prostate cancer. It is particularly effective in early-stage disease or cases where the cancer is confined to the prostate gland. The high-energy radiotherapy damages the DNA of cancer cells, inhibiting their ability to grow and divide, and can result in tumor shrinkage or eradication.
 

Modern radiation treatment devices such as intensity-modulated radiation therapy (IMRT) and image-guided radiation therapy (IGRT) allows the highly precise targeting of the prostate gland. This precision helps minimize damage to surrounding healthy tissues and organs, reducing the risk of side effects. Compared to surgical options including prostatectomy, radiation treatment may have a lower risk of urinary incontinence and erectile dysfunction. Furthermore, radiation therapy is typically delivered on an outpatient basis, allowing patients to return home after each session. This offers convenience and flexibility, as patients can continue their daily activities and maintain their regular routines during treatment. As a result, several benefits associated with the radiation devices in the treatment of prostate cancer will augment the business revenue.
 

Based on end-use, the prostate cancer treatment devices market is segmented as hospitals, specialty clinics, ambulatory surgical centers, cancer research institutes, and others. The hospitals segment dominated the market with 36% revenue share in 2022 and will foresee a similar trend during the forecast timeframe. Hospitals play a crucial role in the treatment of prostate cancer and offer several advantages for patients. Hospitals commonly have multidisciplinary teams consisting of various healthcare professionals including urologists, oncologists, radiologists, pathologists, and nurses. This collaborative approach ensures that patients receive comprehensive and integrated care from experts in different specialties, leading to improved outcomes.
 

Hospitals often have access to advanced medical technologies, equipment, and infrastructure required for the diagnosis, staging, and treatment of prostate cancer. This includes cutting-edge imaging techniques, robotic surgical systems, radiation therapy machines, and specialized laboratories, enabling accurate diagnosis and personalized treatment options. Similarly, hospitals offer a range of supportive care services to enhance the overall well-being of prostate cancer patients. These services may include psychological counselling, pain management, nutritional guidance, physical therapy, and support groups. Thus, numerous benefits related to the hospitals in prostate cancer treatment are driving the segment growth.
 

U.S. dominated the North America region with a significant market share in 2022 and is anticipated to expand at a considerable pace to reach around USD 4.6 billion by 2032. This dominant revenue share is owing to the multiple variables such as increasing prevalence of prostate cancer, favourable reimbursement policies, awareness & screening programs, and R&D activities among others.  Prostate cancer is a significant health concern in the U.S., and the demand for effective treatment options has driven the growth of the prostate cancer treatment devices market in the country. Prostate cancer is one of the most common cancers among men, and the aging population in the U.S. contributes to the growing incidence of this disease.
 

Access to adequate reimbursement for prostate cancer treatment procedures and devices encourages the adoption of advanced treatment technologies. Increased awareness about prostate cancer and the availability of screening programs have also led to early detection and subsequent treatment, thereby driving the demand for treatment devices. Moreover, ongoing R&D activities focused on improving treatment outcomes and reducing side effects have led to the introduction of new and more advanced prostate cancer treatment devices. Thus, the aforementioned variables are projected to drive the country revenue in the near future.
 

Prostate Cancer Treatment Devices Market Share

Some of the major market players operating in the prostate cancer treatment devices market are

• Intuitive Surgical
• Varian Medical Systems
• Elekta
• EDAP TMS
• SonaCare Medical
• Medtronic

Major market players are adopting strategic formulations such as forward integration, new product development, geographical expansion, and research collaborations to garner maximum industry share and promote company growth.
 

Prostate Cancer Treatment Devices Industry News:

• In April 2023, Intuitive Surgical receives FDA clearance of da Vinci SP for simple prostatectomy. In this procedure, the surgeon removes the part of an enlarged prostate that is blocking the flow of urine. The da Vinci SP surgical system will offer trans vesical approach to simple and radical prostatectomy using the da Vinci SP. Thus, this product launch will significantly aid the company in boosting its market presence.
   
• In August 2021, AngioDynamics, Inc. announced it has received approval from the FDA for the PRESERVE pivotal trial of its NanoKnife system for ablation of prostate tissue in an intermediate-risk patient population. The trial was initiated by AngioDynamics in partnership with the Society of Urologic Oncology Clinical Trials Consortium, Inc. This clinical trial assisted the company in augmenting its prostate cancer treatment devices portfolio.
   

This prostate cancer treatment devices market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD (million) from 2018 to 2032 for the following segments:

Click here to Buy Section of this Report

By Device Type

• Radiation Treatment Devices
  • External Beam Radiation Therapy (EBRT)
  • Stereotactic Body Radiation Therapy (SBRT)
  • Proton Therapy
  • Brachytherapy
  • Others
• Surgical Treatment Devices
  • Radical Prostatectomy
  • Robotic Surgery Systems
  • Laparoscopic Devices
  • Others
• Ablation Treatment Devices
  • High-intensity Focused Ultrasound (HIFU)
  • Cryotherapy
  • Laser Ablation
  • Irreversible Electroporation (IRE)
  • Others
• Others

By End-use

• Hospitals
• Specialty Clinics
• Ambulatory Surgical Centers
• Cancer Research Institutes
• Others

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Poland
  • Switzerland
  • The Netherlands
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Indonesia
  • Philippines
  • Vietnam
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Chile
  • Colombia
  • Peru
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Israel
  • Iran
  • Turkey